InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,537.02
(
0.51%
)
US TECH 100
19,641.60
(
0.83%
)
Dow Jones
39,308.00
(
-0.06%
)
Brent Oil
87.33
(
0.48%
)
Bitcoin
58,164.87
(
-3.32%
)
Post# of 4101
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

sarals

Send PM Follow Ignore
Followers 29
Posts 21460
Boards Moderated 4
Alias Born 10/29/2000

sarals

Member Level

Re: 2desire post# 198

Tuesday, 07/10/2001 5:09:50 PM

Tuesday, July 10, 2001 5:09:50 PM

Post# of 4101
Great article, 2desire...

Thought this excerpt had a particularly interesting lead...

Two interesting names
Longman is intrigued by two small companies: Neurocrine Biosciences (NBIX, news, msgs), which owns all the rights to an insomnia drug now in Phase II testing, and Icos (ICOS, news, msgs), which is close to receiving approval for a potency drug that would compete with Pfizer's (PFE, news, msgs) Viagra. While Icos is in a 50-50 partnership with Eli Lilly (LLY, news, msgs), its drug doesn't make people see blue-green, nor does it interact badly with heart drugs, as Viagra does, according to Longman.

Sara


Sara

"I never give them hell. I just tell the truth and they think it's hell." - Harry Truman

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up